# Research Protocol: Systematic Literature Review

## Project Information

| Field | Value |
| --- | --- |
| **Project Title** | Lithium and Alzheimer's Disease Prevention: A Systematic Evidence Review |
| **Principal Investigators** | Family Research Team (Correa/Cohen/Deeble) |
| **Date Initiated** | February 4, 2026 |
| **Protocol Version** | 1.0 |
| **Status** | Completed |

---

## Research Questions

### Primary Question

Is there sufficient scientific evidence to support the hypothesis that lithium supplementation can prevent or slow the progression of Alzheimer's disease?

### Secondary Questions

1. What is the mechanism by which lithium may protect against AD?
2. What is the comparative evidence for lithium orotate vs. lithium carbonate?
3. What are the safety considerations for low-dose lithium in elderly populations?
4. What is the current status of clinical trials?
5. Are the claims in the input document supported by peer-reviewed evidence?

---

## Methodology

### Search Strategy

#### Databases Searched

- [x] PubMed/MEDLINE
- [x] ClinicalTrials.gov
- [x] NIH Research Matters
- [ ] Cochrane Library (not searched)
- [ ] EMBASE (not searched)

#### Search Terms

| Category | Terms |
| --- | --- |
| Intervention | lithium, lithium carbonate, lithium orotate |
| Condition | Alzheimer's disease, dementia, mild cognitive impairment, MCI |
| Study Type | clinical trial, randomized, meta-analysis, systematic review |
| Mechanism | GSK3β, neuroprotection, amyloid, tau |

#### Search Date

February 5, 2026

---

### Inclusion Criteria

| Criterion | Definition |
| --- | --- |
| Study Type | RCTs, meta-analyses, systematic reviews, large observational studies |
| Population | Adults with AD, MCI, or at-risk for dementia |
| Intervention | Any lithium formulation or naturally occurring lithium |
| Comparison | Placebo, other AD treatments, or baseline |
| Outcomes | Cognitive function, biomarkers, disease progression |
| Language | English |
| Date | No restriction |

### Exclusion Criteria

- Case reports and case series (< 10 patients)
- Non-peer-reviewed sources
- Letters and editorials without original data
- Duplicate publications

---

## Sources Evaluated

### Primary Research

| Source | Type | Indexed | Peer-Reviewed |
| --- | --- | --- | --- |
| Aron et al. Nature 2025 | Basic + Translational | ✅ PubMed | ✅ Yes |
| Kessing et al. JAMA Psych 2017 | Epidemiological | ✅ PubMed | ✅ Yes |
| Forlenza et al. BJP 2019 | RCT | ✅ PubMed | ✅ Yes |
| Hampel et al. JCP 2009 | RCT | ✅ PubMed | ✅ Yes |
| Nunes et al. CAR 2013 | RCT | ✅ PubMed | ✅ Yes |
| Matsunaga et al. JAD 2015 | Meta-analysis | ✅ PubMed | ✅ Yes |
| Terao et al. ARR 2024 | Network Meta-analysis | ✅ PubMed | ✅ Yes |

### Secondary/Popular Sources

| Source | Type | Verified | Notes |
| --- | --- | --- | --- |
| Eric Topol Substack | Expert Review | ✅ Yes | Accurate summary of literature |
| NIH Research Matters | Agency Summary | ✅ Yes | Official NIH publication |
| Harvard Gazette | News | ⚠️ 404 Error | Could not access |
| Psychology Today | Popular | ⚠️ 404 Error | Could not access |
| Medscape | Professional | ⚠️ Paywall | Could not access |

---

## Quality Assessment

### GRADE Evidence Levels

| Study Type | Quality | Contribution |
| --- | --- | --- |
| Nature 2025 basic science | High | Strong mechanistic foundation |
| RCTs (small) | Moderate | Consistent positive direction |
| Meta-analyses | Moderate | Pooled evidence strengthens findings |
| Epidemiological | Moderate | Large N, but observational |
| Expert review (Topol) | Lower | Not primary evidence |

### Risk of Bias Assessment

| Bias Domain | Assessment |
| --- | --- |
| Selection bias | Low (RCTs were randomized) |
| Performance bias | Low (double-blind in most RCTs) |
| Detection bias | Low (validated cognitive measures) |
| Attrition bias | Moderate (some dropout) |
| Reporting bias | Low (protocols registered) |
| Publication bias | Unknown (limited trials) |

---

## Synthesis Approach

### Evidence Mapping

1. Extracted key findings from each source
2. Mapped claims against supporting evidence
3. Assessed concordance across study types
4. Identified gaps and contradictions
5. Graded overall confidence

### Claim Verification Process

For each claim in the input document:
1. Identify the specific assertion
2. Search for primary source support
3. Assess quality of supporting evidence
4. Note any contradicting evidence
5. Assign verification status (✅ Verified, ⚠️ Partially supported, ❌ Not supported)

---

## Results Summary

### Claims Verified

| Claim | Sources | Status |
| --- | --- | --- |
| Lithium has neuroprotective effects | Nature 2025, RCTs, meta-analyses | ✅ |
| Low-dose lithium may slow cognitive decline | Forlenza 2019, Nunes 2013 | ✅ |
| Brain lithium is lower in AD | Nature 2025 | ✅ |
| Evidence is promising but not definitive | All sources agree | ✅ |
| Clinical trial is needed before recommendation | Yankner quote, Topol | ✅ |

### Important Caveats Identified

| Finding | Implication |
| --- | --- |
| All human trials used carbonate, not orotate | Orotate efficacy unproven in humans |
| Trials were small (40-80 participants) | Limited statistical power |
| No Phase 3 trials completed | Insufficient for clinical recommendation |
| Supplements unregulated | Quality/purity concerns |
| Kidney/thyroid risks exist | Monitoring required |

---

## Limitations of This Review

1. **Not a registered systematic review** - Did not follow PRISMA
2. **Single reviewer** - No independent validation
3. **Limited database search** - Cochrane, EMBASE not searched
4. **Some sources inaccessible** - 404 errors on several links
5. **No grey literature search** - May miss unpublished data
6. **No meta-analysis performed** - Descriptive synthesis only

---

## Conclusions

### Evidence Supports

- Lithium's neuroprotective properties (strong evidence)
- Association between lithium levels and AD (strong evidence)
- Potential for lithium orotate as therapeutic (moderate evidence - mice only)
- Safety of low-dose lithium (moderate evidence)

### Evidence Does Not Support

- Clinical recommendation for lithium supplementation (premature)
- Specific dosing guidelines (unknown)
- Use of OTC supplements (unregulated)

### Recommendation

The hypothesis that lithium may prevent or treat Alzheimer's disease is **well-supported by scientific evidence**, but translation to clinical practice requires additional human trials, particularly with lithium orotate.

---

## Appendix: PICO Framework

| Element | Definition |
| --- | --- |
| **P**opulation | Adults with MCI, AD, or at risk for dementia |
| **I**ntervention | Lithium (any form) |
| **C**omparator | Placebo, other AD treatments |
| **O**utcome | Cognitive function, biomarkers, disease progression |

---

**Protocol completed February 5, 2026**
